Unicycive Therapeutics Receives FDA Acceptance Of Its NDA Resubmission For Oxylanthanum Carbonate For Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis

Loading news article.

Unicycive Therapeutics Receives FDA Acceptance Of Its NDA Resubmission For Oxylanthanum Carbonate For Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis | WAPE

Unicycive Therapeutics Receives FDA Acceptance Of Its NDA Resubmission For Oxylanthanum Carbonate For Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis

Article summary

Related companies

Analyzed by WAPE AI.

Comments —